Home › Head and Neck Cancer › NCT00568490

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

About the study

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

What is being tested

• Tumor biopsy (procedure)
• Phlebotomy (procedure)

Sponsor: Stanford University · Participants: 200 · Started: Sep 1, 1998

Contact the study team

Official record on ClinicalTrials.gov — NCT00568490

Locations in the U.S.

Conditions

• Head and Neck Cancer
• Lung Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.